Biogen Completes RayThera Acquisition to Expand Immunology
Cambridge, Massachusetts, USA, August 8, 2026 Biogen has completed the acquisition of RayThera Inc., a privately held biotechnology company...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Cambridge, Massachusetts, USA, August 8, 2026 Biogen has completed the acquisition of RayThera Inc., a privately held biotechnology company...
San Diego, California, USA, August 8, 2026 Blacksmith Medicines has announced the publication of new research in the Journal...
SAN DIEGO, California, October 13, 2025 – In a major advancement for antimicrobial innovation, Blacksmith Medicines, Inc. announced that...
